In the workup of patients with suspected hereditary nonpolyposis colorectal cancer (HNPCC), detection of loss of heterozygosity (LOH) could help pinpoint the DNA in the mismatch-repair (MMR) gene carrying the germline mutation, but analysis of microsatellite markers has proved unreliable for this purpose. We developed a simple, low-cost method based on single-nucleotide polymorphism (SNP) genotyping and capillary electrophoresis for the assessment of LOH at 2 MMR loci simultaneously.
scribed (2 ) include pathogenic nonsense or frameshift alterations that lead to loss of the production of protein, missense mutations that can functionally impair the encoded protein, and single-nucleotide polymorphisms (SNPs). The role played by these SNPs is not fully clear, although there is evidence to suggest that they contribute to the development of various types of cancer (3) (4) (5) (6) (7) , including those of the colorectum (8, 9 ) and endometrium (10 ) .
In the well-known 2-hit hypothesis of tumorigenesis, the heterozygous germline mutation of an MMR gene represents the "first hit" in HNPCC, but the loss of the MMR function and the MSI associated with it are observed only after somatic inactivation of the wildtype allele. This "second hit" is believed to be caused in many HNPCC cases by a loss of heterozygosity (LOH). For this reason, LOH assays could be a potentially useful addition to the prescreening protocols used to orient germline testing in individuals with suspected HNPCC. The algorithms currently used to identify HNPCC patients are based largely on various combinations of microsatellite genotyping and immunohistochemistry (IHC) assessment of patterns of MMR protein production. No consensus exists on the order in which these 2 methods should be used, or even on the need to perform both types of testing (11, 12 ) . Although the most accurate results are generally acknowledged to be obtained with a combination of MSI testing and IHC analysis, this approach may not always be feasible or advisable, depending on the laboratory and/or the characteristics of the case at hand (13) (14) (15) (16) (17) . Thus far, the value of LOH assessments in these algorithms has proved to be limited, but the assays in question have been based on the analysis of microsatellite markers (18 ) , which are often unstable in MMR-deficient tumors and thus uninformative for the study of LOH events. LOH can also be detected by multiplex ligation-dependent probe amplification (MLPA) or by DNA sequencing, but MLPA analysis identifies only LOHs that involve changes in exon dosages, and sequencing of DNA extracted from archival tumor tissues is often unsuccessful. In addition, neither of these mutation-detection methods can predict the mutated MMR gene, because their use in LOH assessment is limited to cases in which the germline mutation is already known.
In their recent study of the mechanisms underlying MMR gene inactivation in HNPCC tumors, Ollikainen et al. (19 ) used MALDI-TOF mass spectrometry to quantitatively assess LOH at the sites of germline mutations and in 2 intragenic SNPs in MLH1. Highthroughput SNP-genotyping strategies of this type are extremely attractive in research settings but require robotics and other instrumentation that are still beyond the reach of many clinical genetics laboratories. To further explore the potential of intragenic SNPs as markers of LOH at MMR loci, we used a medium-throughput method based on single-nucleotide primer extension and capillary electrophoresis for SNP genotyping at MLH1 and MSH2 simultaneously. We evaluated the method's performance for detecting LOH and for predicting the gene harboring germline changes in HNPCC patients.
Materials and Methods
The study protocol received institutional review board approval, and written informed consent was obtained from all individuals whose DNA was analyzed. Unless otherwise stated, commercial products were used according to the manufacturers' instructions.
DNA SAMPLES
We analyzed genomic DNA from peripheral blood leukocytes (PBLs) of 20 healthy volunteers of Caucasian origin and DNA from PBL and tumor tissue samples from 67 cancer patients (also of Caucasian origin). Patients 1-42 were known carriers of pathogenic germline mutations in MLH1 or MSH2 (20) (21) (22) (23) (24) (25) (26) . Patients 43-67 were suspected HNPCC probands. Although IHC analysis had demonstrated loss of MLH1 or MSH2 protein production in most of these patients' tumors, DNA sequencing and MLPA analyses had failed to detect germline mutations in any of the major MMR genes. All 67 tumors (66 colorectal cancers, 1 urothelial tumor) had displayed MSI. We used standard phenolchloroform extraction to isolate genomic DNA from most PBL and tumor samples [fresh, frozen, or formalin-fixed and paraffin-embedded (FFPE) samples]. Alternatively, we used the Qiagen QIAamp DNA Mini Kit for some PBL and fresh/frozen tumor tissue samples and the RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion/Applied Biosystems) for some FFPE tumor samples. Table 1 summarizes the characteristics of the 14 SNP markers (7 in MLH1, 7 in MSH2) used in our assay. Targets containing these SNPs were amplified in different reactions, depending on the nature of the template DNA (Fig. 1, Table 1 ). When DNA from PBLs or fresh/ frozen tumors was used, 7 MLH1 and 4 MSH2 fragments (length, 250 -535 bp) were amplified in an undecaplex reaction (Fig. 1A) . In contrast, DNA from FFPE tissues was subjected to 3 quadruplex reactions, yielding a total of 12 amplicons (each Ͻ250 bp; Fig. 1B , Table 1 ). All reactions were carried out in 25-L volumes containing 12.5 L of Multiplex PCR Master Mix (Qiagen), a mixture of primers (each at a final concentration of 0.07-3 mol/L), and up to 100 ng of template DNA. Primer sequences and PCR conditions are provided in Table 1 and the supplemental text, respectively, of the Data Supplement that accompanies the online version of this article at http://www.clinchem. org/content/vol54/issue10.
SNP SELECTION AND MULTIPLEX PCR AMPLIFICATION OF TARGETS

SINGLE-BASE EXTENSION OF SNP-SPECIFIC PRIMERS
We evaluated 35 SNP-specific oligonucleotide primers designed with the ABI PRISM® SNaPshot® Multiplex Kit (Applied Biosystems). To select the 14 primers for multiplex SNaPshot genotyping of the 14 MLH1 and MSH2 SNPs (Table 2) , we used a meticulous, systematic assessment protocol, which included empirical testing in a SNaPshot reaction without a template to exclude self-priming. Each primer consisted of a specific sequence (18 -27 nucleotides long) complementary to the analyzed region plus a poly(GACT) or poly(A) tail, which was added to ensure spatial resolution of the extension products during capillary electrophoresis (final length, 18 -82 nucleotides). Oligonucleotides exceeding 35 nucleotides were purified by HPLC (Generi Biotech).
SNaPshot reactions were carried out in a 10-L final volume containing SNaPshot Multiplex Ready Reaction Mix (5 L), primer mix (final concentrations, 0.02-0.6 mol/L), and templates (4 L) consisting of the multiplex PCR products described above, which had been purified with the QIAquick PCR Purification Kit (Qiagen). Quadruplex PCR products amplified from archival DNA were pooled and purified on the same column before the SNaPshot reaction. The cycling program included 25 cycles of 96°C for 10 s, 50°C for 5 s, and 60°C for 30 s. Extension products were purified by a 15-min incubation with 1 U of shrimp alkaline phosphatase (Promega) at 37°C and a subsequent 15-min incubation at 80°C to inactivate the enzyme. The purified products (0.5 L) were mixed with 9 L of formamide and 0.5 L of GeneScan-120 LIZ Size Standard (Applied Biosystems) and separated by capillary electrophoresis (ABI PRISM 310 Genetic Analyzer; Applied Biosystems). The results were analyzed with GeneMapper 3.0 software (Applied Biosystems).
DNA SEQUENCING AND MLPA
We used AmpliTaq Gold® PCR Master Mix (Applied Biosystems) to amplify fragments for DNA sequencing (primer sequences and cycling conditions available upon request). We used the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) as described previously to sequence purified PCR products (21 ) . MLPA assays for LOH were carried out with the SALSA MLPA Kit P003 MLH1/MSH2 (MRC-Holland). We used an ABI 310 Genetic Analyzer for sequencing and MLPA reactions and analyzed the results with the Sequencing Analysis 5.2 and GeneMapper 3.0 programs, respectively (Applied Biosystems). We used Microsoft Excel sheet data generated according to the MLPA manufacturer's recommendations to determine MLH1/MSH2 exon dosage in DNAs from nonpathologic and tumor samples.
DEFINITIONS OF LOH
SNaPshot
For each SNP marker, we expressed the relative proportions of alleles 1 and 2 in nonpathologic and tumor samples as the ratio of the heights of the corresponding peaks. An LOH index was calculated by dividing the nonpathologic ratio of allele 1 to allele 2 by the corresponding tumor ratio. LOH positivity was defined as an LOH index of Ͻ0.5 (reflecting a substantial loss of allele 1 in the tumor sample) or Ͼ1.5 (indicative of substantial loss of allele 2).
DNA SEQUENCING
When point mutations were detectable as double peaks in the reference DNA, the loss or marked reduction of one of the peaks in the tumor DNA was considered indicative of LOH. In cases characterized by small deletions and/or insertions that shifted the entire sequence downstream from the mutation, LOH positivity was defined as the absence of this shift or a marked reduction of one allele in the mixed pattern of peaks.
MLPA ANALYSIS
Tumor-derived DNA is inevitably contaminated by DNA from nonpathologic tissue within and/or adjacent to the tumor. We therefore defined the homozygous loss of an exon as a decrease in the exon-peak area in tumor DNA of at least 40%, compared with the corresponding peak in the reference DNA containing a heterozygous deletion. Such losses were considered indicative of LOH only when the SD was Ͻ20%.
Results
MLH1 AND MSH2 SNP GENOTYPES BASED ON MULTIPLEX
SNaPshot ANALYSIS VS DNA SEQUENCING
We used PBL DNA from 20 healthy volunteers to compare the results of our SNP-genotyping method with Table 1 ). N, nonpathologic (PBL) DNA; T, tumor DNA; M, size marker; Pro, promoter.
those obtained from DNA sequencing, the current gold standard for genotyping. The genotypes obtained with the 2 methods were concordant for all but 2 SNPs, which are located in MSH2 intron 1 (c.211ϩ9C/G and c.211ϩ98T/C); both SNPs are included in MSH2 amplicon 1 (see Fig. 1A ). In 11 cases, SNaPshot analysis revealed heterozygosity for both of these polymorphisms, whereas sequencing analysis of the same DNAs showed homozygosity at both markers (c.211ϩ9C/C and c.211ϩ98T/T). When we resequenced the SNP at position ϩ9 by means of an amplicon generated with a different primer pair (27 ) , the locus displayed heterozygosity (ϩ9C/G) in all 11 cases.
FREQUENCY OF HETEROZYGOSITY AND INFORMATIVENESS OF THE MLH1 AND MSH2 SNP MARKERS
To estimate the frequency of heterozygosity at the selected SNP markers, we used the SNaPshot-based method to analyze genomic DNA from PBL samples from the 67 unrelated patients with MSI tumors. High heterozygosity rates (Ͼ20%) were observed for all 14 markers (33%-61% for those in MLH1, 21%-52% for MSH2; Table 1 ). The MLH1 and MSH2 marker sets were informative (i.e., at least one of the 7 markers was heterozygous) in 82% and 76% of the samples, respectively, and both sets were informative in 63% of the samples. Table 3 ]. To evaluate the reliability of our LOH-detection method, we reanalyzed tumor DNAs from the 42 patients with known mutations by either DNA sequencing (in the 34 cases characterized by single-base substitutions, small deletions, or insertions) or MLPA (in 8 patients with large germline rearrangements). Table 3 shows that the reference method analysis, which was confined to the heterozygous gene region known to harbor a germline mutation, confirmed all 13 of the LOH events involving MLH1 detected with the SNP-based method and 2 of the 4 events detected in MSH2. The other 2 LOH events at MSH2 (cases 27 and 29) could not be confirmed or excluded because the quality of the tumor DNA was inadequate for MLPA analysis. Of the 9 cases that were uninformative in the SNP-based assays, 6 exhibited LOH in reference assays (cases 7, 25, 34, 40 -42), 2 others (cases 18 and 31) were LOH negative in the reference assay, and sequencing failed in the ninth (case 16) because of poor-quality DNA. In the 16 SNP-infor- mative cases without SNaPshot-detectable LOH, the absence of LOH was confirmed by reference methods in 13 cases; the other 3 samples (cases 6, 26, and 32) could not be sequenced because of the low quality of the DNA. When we compared SNaPshot-based detection of LOH with that based on sequencing and/or MLPA and excluded the 6 cases in which neither reference analysis could be carried out (see Table 2 in the online Data Supplement), the new method exhibited 100% specificity and 71% sensitivity in the combined analysis of MLH1 and MSH2. It displayed excellent sensitivity (93%) for detecting LOH involving MLH1. The low sensitivity (29%) that emerged in the assessment of MSH2 is largely because 2 of the 4 cases of SNaPshotbased LOH detection had to be excluded from the validation analysis because the tumor DNAs could not be analyzed with MLPA. Table 3 shows that SNaPshotbased detection of LOH correctly predicted the gene harboring the germline mutation in 17 (40%) of the 42 cases analyzed [13 (54%) of 24 cases involving MLH1; 4 (22%) of 18 cases in MSH2].
Discussion
We have developed a simple, rapid, and low-cost method for medium-throughput detection of LOH in the MLH1 and MSH2 genes that is based on the simul- 
a Asterisks indicate cases in which the SNaPshot method correctly predicted the gene harboring the germline mutation. b REF, reference method; ϩ, presence of LOH; UI, samples in which all SNPs were uninformative; NA, analysis not applicable; Ϫ, absence of LOH; X, unsuccessful reference method analysis due to inadequate DNA quality.
taneous analysis of multiple SNPs. It involves singlenucleotide primer extension in multiplex SNaPshot reactions followed by capillary electrophoresis and can be used in any laboratory equipped with genetic analyzers. Applied Biosystems claims that its SNaPshot Multiplex Kit can be used to analyze up to 10 SNPs simultaneously, but with meticulous primer selection we succeeded in analyzing all 14 MLH1 and MSH2 SNPs in a single reaction. Interestingly, when we compared SNaPshot genotyping of PBL DNA with SNP genotyping based on DNA sequencing, the new method detected 2 SNPs in MSH2 intron 1 (c.211ϩ9CϾG and c.211ϩ98TϾC) that were missed by the reference method. The failure of DNA sequencing at this locus can probably be linked to the secondary structure of this region, which contains 3 GC-rich motifs that might form a hairpin. This hairpin is likely to be more stable when the template strand contains ϩ9G rather than ϩ9C. This fact may lead to preferential amplification of the ϩ9C allele during the PCR and overrepresentation of this template in the sequencing mix. Like polymerases used in the PCR, the sequencing enzyme is also more likely to preferentially copy the ϩ9C allele. Consequently, the G peak would not be present in the electrophoretogram, and the patient would appear to be homozygous for the ϩ9C allele. Unlike DNA sequencing, the SNaPshot reaction is based on primer annealing immediately adjacent to the SNP position and subsequent extension by a single nucleotide. The chemistry of this reaction is much less susceptible to secondary-structure effects, and both nucleotides will be detected at position ϩ9, even in the presence unequal amounts of the 2 allele-specific amplicons. The same secondary-structure problem might affect the SNP at position ϩ98, which is close to ϩ9. SNaPshot is also better than DNA sequencing for detecting KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in DNA isolated from tumor samples containing admixtures of nonpathologic cells (28 ) . Therefore, regardless of whether the DNA is constitutional or tumoral, SNaPshot surpasses sequencing in terms of its ability to detect single-nucleotide changes in the presence of unequal amounts of allelespecific amplicons.
SNP-based approaches are more reliable for LOH detection than the analysis of microsatellite markers, which are often unstable in MMR-deficient tumors and which are usually located several mega-base pairs from the gene of interest. MALDI-TOF mass spectrometric analysis of 2 intragenic SNP markers has recently been used to investigate the role of LOH in MLH1 inactivation in colorectal and endometrial cancers (19 ) . This approach proved to be very promising, although the authors noted that a higher number of polymorphisms would have improved the rates of heterozygosity. Our SNaPshot-based method was developed around 14 SNPs, each of which presents a heterozygosity frequency of Ͼ20% in the general population. These choices ensured high overall rates of heterozygosity for the MLH1 and MSH2 SNP sets (82% and 76%, respectively, based on an analysis of 67 samples). Compared with the results obtained with DNA sequencing or MLPA analysis of the known mutant locus in 36 tumors, the new method displayed 100% specificity and an overall sensitivity of 71% for detecting LOH at MLH1 or MSH2. The overall sensitivity might well have been higher if we had not had to exclude 2 of the 4 cases of MSH2 LOH from our validation analysis because of technical failure of the reference-method analyses (DNA sequencing and MLPA analysis are both difficult to perform with DNA extracted from tumor samples).
Compared with MALDI-TOF mass spectrometry, SNaPshot-based analysis of intragenic SNPs is associated with substantially lower equipment costs: All that is needed is an automated DNA sequencer. Therefore, our method is especially useful in clinical laboratories involved in the diagnostic workup of patients with suspected HNPCC, where sequencers are already being used for mutation scanning. Assessment of the tumor's MSI status and/or IHC studies of production patterns of MMR proteins are widely used as first-line strategies for selecting cases in which germline testing for MSH2/ MLH1 mutations is indicated. Previous attempts to improve the predictive value of these prescreening protocols with the addition of LOH studies have been unsuccessful (18 ) , but the detection of allelic loss in that study was based on the examination of microsatellite markers, which are (as we have seen) unreliable for this purpose.
Our experience suggests that SNP-based assessment of LOH might have several potential roles in this setting (Fig. 3) . For example, in many laboratories, suspected HNPCC tumors initially undergo PCR-based MSI testing (gray area in Fig. 3) , ideally with the new MSI multiplex typing systems based on quasi-monomorphic markers, which can be used without reference to matching nonpathologic DNA. These kits are much more reliable and cost far less per patient, i.e., approximately US $50 vs US $300 for older methods based on uniplex analyses of a large panel of markers, including dinucleotides, in both nonpathologic and tumoral tissues (29) (30) (31) . Tumors found to be PCR-MSI positive are then subjected to IHC analysis of the production of MMR protein. SNaPshot-based LOH analysis of MSIpositive tumors could be a cost-effective addition to this diagnostic algorithm. This analysis can be performed rapidly on the same DNA samples used for MSI testing, and interpretation of the results is straightfor-ward and objective. Although its ability to predict germline mutations of MLH1 or MSH2 is limited, it is highly specific, and the cost per patient (approximately US $30 for simultaneous analysis of both genes) is considerably lower than for IHC (roughly US $50 for each protein). Therefore, by revealing the presence of MLH1 or MSH2 LOH in an MSI-positive tumor, our method could eliminate further need for IHC analysis and appreciably lower the cost of prescreening in a nonnegligible percentage of cases. This approach could be especially useful when technical difficulties arise in the execution and/or interpretation of IHC assays (32) (33) (34) (35) (36) (37) . The final results of IHC analyses are influenced by several factors, including those related to preparing the FFPE sample (type of fixative, fixation times, temperatures reached during the embedding procedure). The results of SNP-based LOH detection could also be helpful when typical immunostaining for all 4 MMR proteins is observed despite the tumor's MSI positivity and a family history that is strongly suggestive of HNPCC (Fig. 3, right) . In one study (38 ) , nonpathologic production of MMR protein was observed in 8% of MSI-positive tumors, and the rates that have been reported by other groups are only slightly lower (29 ) . Results of this type (admittedly uncommon) can and do occur in the presence of some missense mutations, and LOH detection may identify the mutated gene in some of these cases.
The SNP-genotyping method for MLH1 and MSH2 genes that we have described appears to be a promising, cost-effective adjunct to prescreening protocols used to guide germline testing for MMR defects in patients with colorectal cancers. Its specific roles in this setting can be determined only from data obtained in a large prospective study, which is currently being undertaken by our group. In the meantime, it is also important to recall that this novel assay also has a number of potential roles in research focusing on disease associations with MLH1 and MSH2 SNPs and SNP haplotypes, and it can also be readily adapted to the genetic analysis of other loci exhibiting a high frequency of polymorphisms in the general population. 
